22 and older, any sex, with Upper Airway Surgery. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Surgical Case Completion Rate Using HVNI With or Without Converting to Alternative Mode of OxygenationPrimary· 1 day
For each case, the ability to complete the surgical procedure with use of only Hi-VNI device for oxygenation will be assessed.
Patients were oxygenated with Hi-VNI at a flow rate of 40 L/min and FiO2 of 100%. Patients with spO2 \< 93 or TcCO2 \> 65 during the procedure were converted to an alternative means of oxygenation, including mask ventilation and endotracheal intubation.
The primary outcome measure is the surgical case completion rate with or without converting to alternate means of oxygenation.
Group
Value
95% CI
Patients With HVNI and Patients With Intubation
19
Patients With HVNI and Patients With Intubation
7
Patients With HVNI and Patients With Intubation
5
Sponsor's own description
The goals of this study are to establish the efficacy of Hi-VNI (High Velocity Nasal Insufflation) in upper airway surgery from the anesthesiologist's and surgeon's perspectives, and to describe the ideal patient and the ideal pathology as well as suitable clinical scenarios when this oxygenation technique should be selected.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Natasha Mirza
Last refreshed: 13 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05090852.